What this means
1 and R21 with Matrix-M™, in children aged 5-36 months in Burkina Faso.
A plain-English summary is on its way. Until then, this is the start of the registry's own summary.
- Status
- Active not recruiting
- Who can join
- Ages 5 Months–36 Months
- Where
- 1 site
The science
- Registered title
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M
- Trial ID
- NCT07183371 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Malaria,Falciparum
- What is tested
- R21, RH5.1, R78C, Matrix-M™, Rabivax-S, Menveo, Avaxim 80
- Sponsor
- University of Oxford
- Ages
- 5 Months to 36 Months
- Dates
- First posted Sep 19, 2025 · updated Oct 21, 2026
Registry summary
This is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the malaria vaccine candidates R78C with Matrix-M™, and the combination of RH5.1 and R21 with Matrix-M™, in children aged 5-36 months in Burkina Faso.
Sites (1)
- Institut de Recherche en Sciences de la Sante - Clinical Research Unit of Nanoro (IRSS-URCN), Nanoro, Burkina Faso